A Postauthorization Survey to Document the Therapeutic Management of Oxaliplatin as a First-Line Chemotherapy Regimen in South Africa in Patients with Metastatic Colorectal Cancer

Table 8

Presence of neuropathy.

	Number (%) of patients with neuropathy symptoms
	Total	1	2	3	4
30 days after oxaliplatin treatment discontinuation	87 (48)	46 (25)	18 (10)	20 (11)	2 (1)
2-year followup	9 (5)	5 (5)	4 (4)	—	—

Percentages are calculated out of 195, the total number of patients in the sample. One of the patients with neuropathy symptoms at 30 days after treatment had an unknown symptom grade.
Neuropathy grade refers to the Sanofi-Aventis oncology classification for any neuropathy symptoms: (1) paraesthesia or dysaesthesia not interfering with function; (2) paraesthesia or dysaesthesia interfering with function, but does not interfere with activities of daily living; (3) paraesthesia or dysaesthesia with pain or function impairment that interferes with activities of daily living; (4) persistent paraesthesia or dysaesthesia that is disabling or life-threatening.